ProPure™ Endotoxin-Free Proteins for Reliable Cancer Research
Minimise immune interference in sensitive oncology applications
In cancer research and therapy development, even trace endotoxins can quietly compromise results. From CAR-T and T cell therapies to monoclonal antibodies, ADCs, and bispecific antibodies, these advanced approaches all rely on high-quality recombinant proteins.
Furthermore, during preclinical studies, including animal models for toxicity assessment or cytokine profiling, the presence of endotoxins (LPS) can compromise results and safety. Ensuring endotoxin-free recombinant proteins is therefore essential for both reliable research data and the successful development of next-generation cancer therapeutics.
Invisible interference in cancer therapy and cancer vaccine development
Endotoxin contamination can severely compromise antibody generation in animal models. Even low levels may alter immune responses, reducing antibody specificity, consistency, and overall quality. At the experimental level, endotoxin-contaminated recombinant proteins can subtly—but significantly—alter cellular behaviour through immune stimulatory and cytotoxic effects. In animal studies, endotoxin-induced systemic inflammation may further compromise outcomes, potentially leading to study delays or termination.
In cell-based studies, endotoxin contamination can be a hidden disruptor, particularly in assays that are highly sensitive to LPS. Immune cells such as dendritic cells, macrophages, monocytes, and T cells can respond strongly even to trace amounts of endotoxin, leading to cytokine release, altered proliferation, or unexpected activation. These effects can easily produce misleading or non-reproducible results.
The demand for endotoxin-free reagents is even more critical in the development of cancer vaccines. Since these therapies rely on precise modulation of the immune system, any LPS contamination can trigger unintended immune activation, mask the true efficacy of the vaccine candidate and introduce safety risks. Using endotoxin-free proteins is therefore critical to accurately evaluate immunogenicity and support safe clinical translation.
Sino Biological’s ProPure™ solution to minimise endotoxin risk
While pharmacopeial guidelines such as USP <85> provide general limits for endotoxin, cutting-edge immunology and translational oncology studies often require far stricter control. Sino Biological’s ProPure™ endotoxin-free recombinant proteins are designed to eliminate this variable at the source, supporting reliable results from early discovery through IND-enabling studies.
Produced at the state-of-the-art Center for Bioprocessing (C4B) in Texas, US, ProPure™ reagents are rigorously controlled to achieve levels as low as 0.05 EU/mg, with select products reaching an exceptional 0.01 EU/mg—over ten times lower than typical industry standards.
By incorporating endotoxin-free proteins, researchers in cancer therapy and cancer vaccine development can confidently achieve consistent and accurate results in critical applications, including:
- Animal immunisation for antibody generation – ensuring high-quality antibodies and predictable host immune responses.
- Preclinical toxicology and pharmacokinetics (PK) – minimising confounding immune activation in animal models.
- In vitro cell proliferation and differentiation assays – reducing false positives caused by LPS-sensitive cells such as dendritic cells, macrophages, and T cells.
- Precise detection and quantification of cytokines – supporting reliable immunological readouts and biomarker analyses.
How does ProPure™ achieve ultra-low endotoxin levels?
ProPure™ quality is not achieved by end-stage cleanup alone. C4B employs an integrated Prevention–Isolation–Detection strategy across the entire production lifecycle.
- Prevention at the source: Endotoxin-free plasmids and buffers, low endotoxin-binding plastics, and stringent CIP procedures minimise LPS introduction from cloning through purification.
- Environmental isolation: An E. coli-free production system eliminates a major source of endotoxin introduction.
- Dual detection: Each batch is tested using both LAL and/or recombinant Factor C (rFc) assays for sensitive, redundant detection and fully traceable batch data.
This end-to-end design ensures that ProPure™ proteins arrive ready for use in the most demanding oncology and immunology applications, without requiring researchers to add extra purification steps that can damage protein quality or delay timelines.
Figure 1. ProPure™ Triple-Control Strategy for Ultra-Low Endotoxin.
Summary
With advanced technologies and rigorous quality control, Sino Biological delivers endotoxin-free proteins that meet the needs of highly sensitive research and translational applications. ProPure™ proteins help researchers reduce variability, improve reproducibility, and accelerate the development of next-generation cancer therapies.
